<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00508664</url>
  </required_header>
  <id_info>
    <org_study_id>TP(F)+Radiation+/-Cetuximab</org_study_id>
    <nct_id>NCT00508664</nct_id>
  </id_info>
  <brief_title>Docetaxel, Cisplatin (TP) + Radiation +/- Cetuximab in Larynx Carcinoma (CA)</brief_title>
  <acronym>DeLOS II</acronym>
  <official_title>Randomised Phase II Screening Study to be Used in an TP/TPF-chemotherapy (Short Induction) Before TP/TPF-induction, Radiotherapy With or Without Cetuximab in the Primary Therapy of the Only by Laryngectomy Operable Carcinoma of the Larynx/Hypopharynx</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ClinAssess</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Leipzig</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The DeLOS II trial is a multicenter randomised phase II trial investigating a&#xD;
      TP/5-Fluorouracil (TPF)-chemotherapy with or without cetuximab for Patients with only by&#xD;
      laryngectomy operable carcinoma of the larynx/hypopharynx. Patients were divided in responder&#xD;
      or non-responder after 4 weeks. Since August 2009 Responder receive TP with or without&#xD;
      Cetuximab + radiation. (Until february 2009 Responder received TPF with or without Cetuximab&#xD;
      + radiation.) Planned accrual is 85 patients per treatment arm. The primary study endpoint is&#xD;
      a confirmatory proof of an adequate survival rate with a functionally larynx-conserving 2&#xD;
      years after randomisation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Confirmatory proof of an adequate survival rate with a functionally larynx-conserving 2 years after randomisation</measure>
    <time_frame>LFS-rate 2 years after randomisation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Descriptive analysis of the study arms concerning the secondary end criteria of the study</measure>
    <time_frame>LSF 2 years after randomisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Explorative comparison of the study arms concerning the primary and secondary end criteria of the study</measure>
    <time_frame>LSF 2 years after randomisation</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">180</enrollment>
  <condition>Squamous Cell Carcinoma of the Hypopharynx</condition>
  <condition>Larynx Carcinoma</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TP + Radiation (TPF until Feb 2009)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TP + Cetuximab + Radiation (TPF until Feb 2009)</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation</intervention_name>
    <description>Radiation start in week 11</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <description>Day 1 400mg/m2 i.v. than weekly 250 mg/m2 i.v. for 16 weeks</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>75 mg/m2 i.v. day 1 3 times</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <other_name>Taxotere</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin (TP)</intervention_name>
    <description>75 mg/m2 i.v. day 1 3 times</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-Fluorouracil (TPF) (only until Feb 2009)</intervention_name>
    <description>Only patients recruited until Feb 2009: 750 mg/m2 i.v. day 1-5, 3 times</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed, primary only with laryngectomy respectable squamous-cell&#xD;
             carcinoma of the larynx or hypopharynx&#xD;
&#xD;
          -  T3-T4a carcinoma of the glottis&#xD;
&#xD;
          -  T2-T4a carcinoma of the supraglottic, only controllable by laryngectomy and if&#xD;
             applicable by root of tongue segmental resection&#xD;
&#xD;
          -  T2-T4a carcinoma of the hypopharynx only controllable by laryngectomy (for example T2,&#xD;
             post cricoidal) and hypopharynx segmental resection&#xD;
&#xD;
          -  N-status: cervical metastases (N0-N3) have to be rehabilitate by surgical procedures&#xD;
&#xD;
               -  Blood count: Leukocytes &gt;3500/mm\3, Neutrophils &gt; 1500/ mm\3, Thrombocytes &gt;&#xD;
                  8000/ mm\3&#xD;
&#xD;
               -  Clinical chemistry:&#xD;
&#xD;
          -  adequate renal function, defined by serum creatinine and urea not higher than 25%&#xD;
             upper NL, creatinine-clearance &gt; 60 ml/min/1,72 m\2&#xD;
&#xD;
          -  adequate hepatic function with SGOT, SGPT not higher than 50% and bilirubin not higher&#xD;
             than upper NL&#xD;
&#xD;
          -  electrolytes at NL&#xD;
&#xD;
               -  anesthetic risk normal or low-grade elevated&#xD;
&#xD;
               -  age 18-75 years&#xD;
&#xD;
               -  written informed consent&#xD;
&#xD;
               -  effective contraception after individual advice for men and women if there is a&#xD;
                  possibility of reproductive potential (effective contraception are: oral&#xD;
                  contraception with estrogen and gestagen (no minipill), vaginal ring,&#xD;
                  contraception patch, estrogen free ovulation suppressors, hormone spiral with&#xD;
                  progesterone, injection for three month with depot gestagen, hormone releasing&#xD;
                  implantation (luteal hormone containing rod), abstinence or sterilization&#xD;
                  (vasectomy) of the male)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  primary cancer treatable by operational larynx -conserving procedures&#xD;
&#xD;
          -  distant metastases (M1-Status)&#xD;
&#xD;
          -  total tumor volume exceeding 80 ml or larynx skeleton punctuated with infiltration of&#xD;
             surrounding soft tissues respectively the esophageal aditus (exclusive cartilage&#xD;
             infiltration represents no exclusion criteria)&#xD;
&#xD;
          -  tumor-specific prior chemo or radiotherapy&#xD;
&#xD;
          -  metachronous or synchronous malignant tumor (exception basalioma) [in case of a&#xD;
             controlled tumor of different localization with a non-treated interval over 5 years to&#xD;
             the present therapy the patient can be included after consultation with the&#xD;
             coordinating investigator]&#xD;
&#xD;
          -  life expectancy &lt; 3 month&#xD;
&#xD;
          -  Karnofsky performance status &lt; 70%&#xD;
&#xD;
          -  serious cardiopulmonary concomitant disease (cardiac insufficiency grade III and IV&#xD;
             according NYHA status, myocardial infarction, angina pectoris, respiratory global&#xD;
             insufficiency)&#xD;
&#xD;
          -  Chronic diseases with permanent-therapy (uncontrolled diabetes, active rheumatoid&#xD;
             arthritis)&#xD;
&#xD;
          -  recurrent pneumonia, COPD GOLD stage &lt;2, chronic inflammation of intestine or any&#xD;
             other concomitant diseases, which disallow study participation in the opinion of the&#xD;
             responsible physician&#xD;
&#xD;
          -  Other circumstances (contra-indications), which disallow treatment with Docetaxel,&#xD;
             Cisplatin, 5-FU, Cetuximab or radiotherapy&#xD;
&#xD;
          -  Expected absent patient compliance&#xD;
&#xD;
          -  Periodic follow-up not possible (for example address outside germany)&#xD;
&#xD;
          -  Pregnant or breast-feeding woman&#xD;
&#xD;
          -  Absent or constricted legal capacity&#xD;
&#xD;
          -  Participation to another clinical trial with any investigational study within 30 days&#xD;
             prior to study screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas Dietz, Dr. med.</last_name>
    <role>Study Director</role>
    <affiliation>University of Leipzig</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitätsklinik für HNO</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Landeskrankenhaus Klagenfurt</name>
      <address>
        <city>Klagenfurt</city>
        <zip>A-9020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allgemeines Krankenhaus der Stadt Wien</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helios Klinikum Erfurt GmbH Klinik für HNO-Heilkunde, Plastische Operationen</name>
      <address>
        <city>Erfurt</city>
        <state>Thüringen</state>
        <zip>99089</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik Aachen</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité, Campus Benjamin Franklin</name>
      <address>
        <city>Berlin</city>
        <zip>12200</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Neukölln, Vivantes GmbH</name>
      <address>
        <city>Berlin</city>
        <zip>12351</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Bielefeld-Mitte</name>
      <address>
        <city>Bielefeld</city>
        <zip>33604</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Malteser Krankenhaus St. Anna gGmbH, HNO-Klinik</name>
      <address>
        <city>Duisburg</city>
        <zip>47259</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Fulda gAG, Klinik für Hals-Nasen-Ohrenkrankheiten</name>
      <address>
        <city>Fulda</city>
        <zip>36043</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Hannover Nordstadt</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Jena</name>
      <address>
        <city>Jena</city>
        <zip>07743</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincentius Kliniken</name>
      <address>
        <city>Karlsruhe</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Kassel GmbH</name>
      <address>
        <city>Kassel</city>
        <zip>34125</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Katholisches Klinikum Koblenz Marienhof</name>
      <address>
        <city>Koblenz</city>
        <zip>56073</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik Köln</name>
      <address>
        <city>Köln</city>
        <zip>50924</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universtitätsklinikum Schleswig-Holstein</name>
      <address>
        <city>Lübeck</city>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Großhadern</name>
      <address>
        <city>München</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Fakultät der Westfälischen Wilhelms-Universität Münster</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Südharz-Krankenhaus Nordhausen gGmbH</name>
      <address>
        <city>Nordhausen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Ernst von Bergmann gGmbH</name>
      <address>
        <city>Potsdam</city>
        <zip>14467</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universtitätsklinikum Regensburg</name>
      <address>
        <city>Regensburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Stuttgart Katharinenhospital, Klinik für HNO-Krankheiten</name>
      <address>
        <city>Stuttgart</city>
        <zip>70174</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bayerischen Julius Maximillians-Universtät Würzburg</name>
      <address>
        <city>Würzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <study_first_submitted>July 27, 2007</study_first_submitted>
  <study_first_submitted_qc>July 27, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 30, 2007</study_first_posted>
  <last_update_submitted>June 1, 2015</last_update_submitted>
  <last_update_submitted_qc>June 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Leipzig</investigator_affiliation>
    <investigator_full_name>ClinAssess</investigator_full_name>
    <investigator_title>Prof. Dietz, Universität Leipzig</investigator_title>
  </responsible_party>
  <keyword>by laryngectomy operable carcinoma of the larynx and the hypopharynx</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Laryngeal Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

